Quantcast

Latest Quinazolines Stories

2009-05-06 07:00:00

Current and Emerging Targeted Therapies Such As AstraZeneca's Iressa and Roche's Avastin Will Drive the Market From 2008 to 2013, According to a New Report from Decision Resources WALTHAM, Mass., May 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the non-small-cell lung cancer drug market in China will more than double by 2013, growing from $307 million in 2008 to $648 million in 2013....

2009-05-05 08:00:00

Test will help oncologists guide treatment of patients with non-small cell lung cancer BROOMFIELD, Colo., May 5 /PRNewswire/ -- Biodesix, Inc. today announces U.S. commercial availability of VeriStrat, a unique, blood-based, proteomic test for patients with advanced stage non-small cell lung cancer (NSCLC). VeriStrat identifies patients who are likely to have good or poor outcomes following treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as...

2009-04-29 14:10:55

An oral medication could help some patients with inflammatory breast cancer. Aggressive forms of inflammatory breast cancer can be difficult to treat, often unresponsive to chemotherapy, radiation or approved medications. For patients whose disease is resistant to anthracycline or taxane and trastuzumab treatment, options are limited. However, a new study of the oral growth inhibitor, lapatinib, showed promise for patients for which all other treatment options have failed. Patients were given...

2009-04-19 09:30:39

Finally some promising news about pancreatic cancer, one of the most fatal cancers, due to the difficulties of early detection and the lack of effective therapies: Johns Hopkins University pathologist Akhilesh Pandey has identified an epidermal growth factor receptor aberrantly active in approximately a third of the 250 human pancreatic cancers studied.In a presentation April 18, at Experimental Biology 2009 in New Orleans, Dr. Pandey explained why this finding and related work in his Hopkins...

2009-04-01 08:00:00

LONDON and PHILADELPHIA, April 1, /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced the submission of two simultaneous regulatory applications to expand the use of TYVERB(R)/TYKERB(R) (lapatinib). If approved, TYVERB(R)/TYKERB(R) could be used as a first-line therapy regimen combined with anti-hormonal therapy for patients with hormone-sensitive, metastatic (or advanced) breast cancer in Europe and the United States. The variation to the EU marketing authorization and...

2008-12-04 12:39:59

A breast cancer chemotherapy drug shows benefits in fighting one type of breast cancer but not another type, U.S. researchers say. The study, published in the journal Clinical Cancer Research, found the oral chemotherapy drug lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer, or those who express EGRF alone, derive no incremental benefit. In addition, a misclassification of metastatic breast cancer patients by as much as 10 percent...

af7cb6fe1aa746fdbe430814fe2c7b311
2008-11-21 12:27:27

A recent study suggests that advanced lung cancer patients might be able to avoid another chemotherapy treatment by taking a targeted pill treatment. An international study showed patients on Iressa, an expensive, newer targeted treatment, survived about as long as those on another course of chemotherapy. "This will provide us with another drug in our armory," said Dr. Michael Seckl, head of Cancer Research UK's Lung Cancer Group at Imperial College in London. Seckl was not connected to the...

2008-11-07 12:00:23

Genentech, a biotechnology company, and OSI Pharmaceuticals, have announced that a global Phase III study has met its primary endpoint and showed that Tarceva significantly extended the time patients with advanced non-small cell lung cancer lived without their cancer getting worse when given immediately following initial treatment with platinum-based chemotherapy, compared to placebo. Saturn is a placebo-controlled, randomized, double-blind, Phase III study conducted by Roche that enrolled...

2008-11-07 03:00:04

Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a global Phase III study (SATURN) met its primary endpoint and showed Tarceva(R) (erlotinib) significantly extended the time patients with advanced non-small cell lung cancer (NSCLC) lived without their cancer getting worse when given immediately following initial treatment with platinum-based chemotherapy, compared to placebo. There were no new or unexpected safety signals in the study and adverse...

2008-10-23 15:00:28

U.S. scientists say an early trial of a multi-kinase inhibitor has shown impressive tumor shrinkage in patients with a hard-to-treat form of thyroid cancer. Assistant Professor Pasi Janne of Harvard University Medical School and Professor Steven Sherman of the M.D. Anderson Cancer Center said the encouraging results have put the drug's development on a fast track, prompting the accelerated initiation of a large phase III trial. The compound, XL184, targets cell growth and migration, as...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related